| Autor: |
CatalYm |
| Zdroj: |
Business Wire (English). 07/20/2023. |
| Abstrakt: |
CatalYm today announced the publication of preclinical data in Nature Communications under the title “Tumor-derived GDF-15 blocks LFA-1 dependent T cell recruitment and suppresses responses to anti-PD-1 treatment”. The study reveals a central role of GDF-15 in the resistance of tumors to current immunotherapy. These findings further highlight the therapeutic significance of CatalYm’s proprietary anti-GDF-15 antibody candidate, visugromab, currently in advanced Phase 2 clinical studies. [ABSTRACT FROM PUBLISHER] |
| Databáze: |
Regional Business News |
| Externí odkaz: |
|
|
Nepřihlášeným uživatelům se plný text nezobrazuje |
K zobrazení výsledku je třeba se přihlásit.
|
